Physician profile
Vinay Gupta
NPI 1629224357
$34,474.56
in general payments reported to CMS, 2019-2025
38 companies · $2,419 in 2025
The $2,419 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,742 · 2022: $25K · 2023: $10.85 · 2024: $2,279 · 2025: $2,419.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,646 · Education: $62.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,646.09 |
| Education | $62.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mckesson Corporation | $25,000.00 | 2022 | |
| Glaxosmithkline, LLC. | $2,988.60 | 2021-2025 | Ojjaara, Jemperli, Zejula |
| Novartis Pharmaceuticals Corporation | $2,264.97 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $739.50 | 2024-2025 | Enhertu, Calquence, Imfinzi |
| Abbvie INC. | $509.52 | 2024-2025 | |
| Pfizer INC. | $392.33 | 2024-2025 | |
| Gilead Sciences, INC. | $351.15 | 2021-2025 | Trodelvy |
| Merck Sharp & Dohme LLC | $340.67 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Genzyme Corporation | $242.67 | 2024-2025 | |
| Genentech USA, INC. | $190.49 | 2024-2025 | Tecentriq, Venclexta, Itovebi |
| Daiichi Sankyo INC. | $121.91 | 2024-2025 | Enhertu, Injectafer |
| Regeneron Healthcare Solutions, INC. | $120.80 | 2024-2025 | Libtayo, Lynozyfic |
| Array Biopharma INC | $119.42 | 2024-2025 | Braftovi, Mektovi, Lorbrena |
| Incyte Corporation | $100.76 | 2024-2025 | Monjuvi, Jakafi, Zynyz |
| E.R. Squibb & Sons, L.L.C. | $98.31 | 2024-2025 | Opdivo |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $95.06 | 2024-2025 | Vyloy, Xospata, Xtandi |
| Sobi, INC | $90.91 | 2024-2025 | |
| Celgene Corporation | $89.51 | 2024-2025 | Reblozyl, Pomalyst |
| Eisai INC. | $68.12 | 2024-2025 | |
| Exelixis INC. | $52.02 | 2024 | Cabometyx |
| Stemline Therapeutics INC. | $51.56 | 2024 | Orserdu |
| Recordati_rare_diseases_inc. | $45.51 | 2025 | Enjaymo, Sylvant |
| Aveo Pharmaceuticals, INC. | $44.57 | 2024-2025 | |
| Janssen Biotech, INC. | $40.46 | 2025 | Rybrevant |
| Takeda Pharmaceuticals U.S.A., INC. | $38.04 | 2024-2025 | Alunbrig, Iclusig |
| Rigel Pharmaceuticals, INC. | $37.59 | 2024 | Tavalisse, Rezlidhia |
| Servier Pharmaceuticals LLC | $35.29 | 2024 | |
| Caris Mpi, INC. | $27.22 | 2025 | Mi Cancer Seek |
| Legend Biotech USA INC. | $26.53 | 2025 | Carvykti |
| Karyopharm Therapeutics INC. | $23.80 | 2022 | |
| Medtronic, INC. | $21.25 | 2025 | Synchromedii |
| Tempus Ai, INC | $19.78 | 2024 | Xt Cdx |
| Geron Corporation | $19.36 | 2025 | Rytelo |
| Bayer Healthcare Pharmaceuticals INC. | $17.86 | 2024 | |
| Tersera Therapeutics LLC | $17.02 | 2024 | Zoladex |
| Iovance Biotherapeutics, INC. | $16.81 | 2024 | Amtagvi |
| Lilly USA, LLC | $15.19 | 2025 | Verzenio |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vinay Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.